BiotechTube
Eclipse Regenesis

Eclipse Regenesis

San Diego, United States· Est.
eclipseregenesis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Eclipse Regenesis is developing the first device-based therapy aimed at regenerating intestinal tissue in patients with Short Bowel Syndrome (SBS), a severe and costly condition. Its Eclipse XL1 System is an implantable coil that applies gentle pressure to the intestine to stimulate natural growth (distraction enterogenesis), addressing the root cause of malabsorption. The company is currently conducting a feasibility study in partnership with leading pediatric hospitals and operates as a private, pre-revenue entity focused on bringing this regenerative approach to market.

GastroenterologyRare Diseases

Technology Platform

Device-based distraction enterogenesis platform; an implantable coil that applies gentle radial pressure to stimulate endogenous intestinal tissue growth and lengthening.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

The primary opportunity is to establish a new, potentially curative standard of care for Short Bowel Syndrome, a condition with high unmet need and enormous lifetime costs of care.
Success could lead to expansion into other gastrointestinal disorders requiring tissue adaptation or regeneration.
The device-based, one-time procedure model offers a compelling value proposition to payers compared to lifelong biologic therapy or transplantation.

Risk Factors

Key risks include clinical failure of the novel enterogenesis mechanism to produce functional intestinal growth in humans, regulatory challenges for a first-in-class device, and securing reimbursement from payers for a high-cost intervention.
The company also faces adoption risk, as it must convince surgeons to move from established management strategies to a new regenerative procedure.

Competitive Landscape

Eclipse competes against the standard of care: lifelong Total Parenteral Nutrition (TPN) and drug therapy (teduglutide). Its primary differentiator is its aim to regenerate functional intestine, a structural solution versus a management one. It also faces future competition from other regenerative approaches (e.g., tissue engineering, stem cell therapies) and improved pharmacologics, but currently has a first-mover advantage in device-based intestinal lengthening.

More companies in Regenerative Medicine →More companies in United States →